deltatrials
Completed PHASE1 NCT00000689

Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Conditions HIV Infections Lymphoma, Non-Hodgkin
Interventions Bleomycin sulfate Cyclophosphamide Cytarabine Dexamethasone Doxorubicin hydrochloride Leucovorin calcium Methotrexate Sargramostim Vincristine sulfate
Updated 7 times since 2017 Last updated: Oct 26, 2021 Completion: Mar 31, 1991

Listed as NCT00000689, this PHASE1 trial focuses on HIV Infections and Lymphoma, Non-Hodgkin and remains completed. Sponsored by National Institute of Allergy and Infectious Diseases (NIAID), it has been updated 7 times since 2026, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Dec 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jan 2021 — Dec 2021 [monthly]

    Completed PHASE1

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE1

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Institute of Allergy and Infectious Diseases (NIAID)
Data source: National Institute of Allergy and Infectious Diseases (NIAID)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Los Angeles, United States